Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Alessandra Tucci, MD, Anna Guidetti, MD, Anna Dodero, MD, Francesca Schieppati, MD, Alessandro Re, MD, Nicola Bianchetti, MD, Chiara Bottelli, MD, Angela Passi, MD, Maria Miscio, Simona Fisogni, MD, Piera Balzarini, Fabio Facchetti, MD, Paolo Corradini, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4154.

https://doi.org/10.1182/blood.V130.Suppl_1.4154.4154

Published: 2017

Journal Articles

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Anna Dodero, MD, Anna Guidetti, MD, Alessandra Tucci, MD, Alessio Pellegrinelli, Antonello Cabras, MD, Liliana Franca Devizzi, MD, Lucia Farina, Luca Pappalettera, MD, Alberto Mussetti, MD, Maria Chiara Di Chio, MD, Rosa Jessica, MD, Martina Soldarini, MD, Angela Passi, MD, Paola Matteucci, MD, Stefano A. Pileri, Giuseppe Rossi, MD, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 2844.

https://doi.org/10.1182/blood.V130.Suppl_1.2844.2844

Published: 2017

Journal Articles

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Alessandro Re, MD, Chiara Cattaneo, MD, Salvatore Casari, MD, Annalisa Peli, MD, Nicola Bianchetti, MD, Angela Passi, MD, Emanuele Focà, MD, Maria Miscio, Francesco Castelli, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 5223.

https://doi.org/10.1182/blood.V130.Suppl_1.5223.5223

Published: 2017

Journal Articles

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

Chiara Cattaneo, MD, Doriana Gramegna, Chiara Pagani, MD, Erika Borlenghi, Michele Malagola, MD, Elisa Cerqui, MD, Angela Passi, MD, Francesca Schieppati, MD, Claudia Crippa, MD, Daniela Dalceggio, Cecilia Carbone, MD, Anna Maria Pelizzari, Margherita Sciumé, Alessandro Re, MD, Domenico Russo, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2288.

https://doi.org/10.1182/blood.V130.Suppl_1.2288.2288

Published: 2017

Journal Articles

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

Francesca Schieppati, MD, Angela Passi, MD, Erika Borlenghi, MD, Cinzia Lamorgese, Giuseppina Ruggeri, MD, Marco Chiarini, MSc, Viviana Giustini, MSc, Michele Malagola, MD, Chiara Cattaneo, MD, Margherita Sciumé, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3931.

https://doi.org/10.1182/blood.V130.Suppl_1.3931.3931

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

Journal Articles

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

Mariella D'Adda, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Angela Passi, MD, Francesca Schieppati, MD, Rosaria Scaduto, Giuseppe Rossi, MD

Blood (2016) 128 (22): 5455.

https://doi.org/10.1182/blood.V128.22.5455.5455

Published: 2016

Journal Articles

Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)

Francesca Schieppati, MD, Simona Fisogni, MD, Piera Balzarini, PhD, Alessandro Re, MD, Luisa Lorenzi, MD, Daniela Dalceggio, MD, Angela Passi, MD, Chiara Cattaneo, MD, Fabio Facchetti, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2016) 128 (22): 5295.

https://doi.org/10.1182/blood.V128.22.5295.5295

Published: 2016

Journal Articles

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Erika Borlenghi, MD, Mirko Farina, MD, Angela Passi, MD, Chiara Pagani, MD, Elisa Cerqui, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marta Petullà, PharmD, Angelo Belotti, MD, Giuseppina Ruggeri, Giuseppe Rossi, MD

Blood (2016) 128 (22): 3993.

https://doi.org/10.1182/blood.V128.22.3993.3993

Published: 2016

Journal Articles

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Erika Borlenghi, MD, Mirko Farina, MD, Marco Chiarini, MSC, Viviana Giustini, MSC, Cinzia Lamorgese, Angela Passi, MD, Enrico Morello, MD, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2016) 128 (22): 2882.

https://doi.org/10.1182/blood.V128.22.2882.2882

Published: 2016

Journal Articles

Antibiotic Prophylaxis Revisited: The Impact of Fluoroquinolones on Epidemiology and on the Emergence of Resistant Strains in Acute Leukemia Patients. Results of a Prospective Study By the Rete Ematologia Lombarda (REL)

Chiara Cattaneo, MD, Patrizia Zappasodi, MD, Silvia Ferrari, MD, Francesca Pavesi, MD, Claudio Annaloro, MD, Cristina Skert, MD, Luisa Verga, MD, Elisabetta Todisco, MD, Andrea Ferrario, MD, Vittoria Saccà, Angela Passi, MD, Erika Borlenghi, MD, Matteo C Da Vià, MD, Valentina Mancini, Gabriella Mometto, Claudia Basilico, MD, Roberto Cairoli, Annamaria Nosari, Giuseppe Rossi, MD

Blood (2014) 124 (21): 4125.

https://doi.org/10.1182/blood.V124.21.4125.4125

Published: 2014

NARROW

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Antibiotic Prophylaxis Revisited: The Impact of Fluoroquinolones on Epidemiology and on the Emergence of Resistant Strains in Acute Leukemia Patients. Results of a Prospective Study By the Rete Ematologia Lombarda (REL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only